Camurus announced that Brixadi (buprenorphine) extended-release injection, a weekly and monthly medication for the treatment of moderate to severe opioid use disorder (OUD), is now available in the US for patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with a daily buprenorphine product. Brixadi should be used as part of a complete treatment plan that includes counseling and psychosocial support. Brixadi is formulated based on Camurus' proprietary FluidCrystal®?

injection depot technology and is marketed in the US by Braeburn under a license agreement with Camurus. Brixadi is the first and only buprenorphine product that offers weekly and monthly doses. Patients currently being treated with oral buprenorphine-containing products can be switched directly to either Brixadi Weekly or Brixadi Monthly in accordance with equivalent doses suggested in the Prescribing Information.

OUD is a complex and potentially life-threatening condition with a significant negative impact on the individual, their families, and society. The US prevalence of OUD is estimated to be between 6-7 million people; of these approximately 3 million are diagnosed with OUD, with about half receiving medical treatment.